SNDX
USDSyndax Pharmaceuticals Inc. Common Stock
リアルタイム価格
価格チャート
主要指標
市場指標
始値
$13.600
高値
$15.799
安値
$13.150
出来高
3.36M
企業ファンダメンタルズ
時価総額
1.3B
業種
バイオテクノロジー
国
United States
取引統計
平均出来高
2.67M
取引所
NMS
通貨
USD
52週レンジ
関連ニュース
UBS Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $38
UBS analyst David Dai maintains Syndax Pharmaceuticals with a Buy and raises the price target from $35 to $38.
Barclays Maintains Overweight on Syndax Pharmaceuticals, Raises Price Target to $22
Barclays analyst Peter Lawson maintains Syndax Pharmaceuticals with a Overweight and raises the price target from $19 to $22.
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
– 12 revumenib and 11 axatilimab abstracts accepted, including 6 oral presentations, underscoring Syndax's leadership in menin inhibition and CSF-1R inhibition – – Revumenib abstracts showcase compelling results in
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an
Syndax Announces Participation in November Investor Conferences
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (NASDAQ:SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third
HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Syndax Pharmaceuticals with a Buy and maintains $40 price target.
